

Kara Kapke (317) 231.6491 kara.kapke@btlaw.com 11 S. Meridian Street Indianapolis, IN 46204-3535 U.S.A. (317) 236-1313 Fax (317) 231-7433

www.btlaw.com

June 2, 2023

Special Master the Honorable Thomas Vanaskie Stevens & Lee 1500 Market Street, East Tower, 18<sup>th</sup> Floor Philadelphia, PA 19103

RE: In re: Valsartan, Losartan, and Irbesartan Products Liability Litigation
United States District Court for the District of New Jersey, Case No.: 1:19-md-2875

Dear Special Master Vanaskie:

On behalf of Defendants Albertson's LLC, CVS Pharmacy, Inc., Express Scripts, Inc., Humana Pharmacy, Inc., Kroger Co., OptumRX, Optum, Inc., Rite Aid Corp., Walgreen Co., and Walmart Inc.) (collectively, the "Retail Pharmacy Defendants"), please find enclosed a proposed order regarding a briefing schedule for the parties to address any outstanding issues associated with the form of the Retail Pharmacy Defendants' production of the CMO 32 items (TPP payments, costs, profits, and custodial discovery).

The parties have met and conferred numerous times regarding CMO 32 and appear close to reaching an agreement on a number of issues regarding form of the Retail Pharmacy Defendants' production of the CMO 32 items, but in the event that there remains a discrete issue of interpreting CMO 32 that the parties disagree upon, the parties jointly request that the Court enter the following scheduling for submission of briefing, which mirrors the schedule adopted by the Court for the discovery from the Wholesalers:

June 13, 2023 – Retail Pharmacy Defendants shall file their initial letter brief regarding their proposed interpretation of CMO 32;

June 27, 2023 – Plaintiffs shall file their response/opposition to the Retail Pharmacy Defendants' initial letter brief;

June 30, 2023 - Retail Pharmacy Defendants may file a letter reply brief, not to exceed two pages; and

July 6, 2023 – The Special Master will hold oral argument via Zoom on the parties' disputes at 11:00 a.m.

Plaintiffs' counsel has reviewed this letter and the proposed order and consents to this submission.

Thank you once again for your consideration of these issues.

Respectfully submitted,

Kara Kapke Kara Kapke